Cargando…
A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth
Breast cancer is a heterogeneous disease consisting of several subtypes. Among these subtypes, triple negative breast cancer is particularly difficult to treat. This is due to a lack of understanding of the mechanisms behind the disease, and consequently a lack of druggable targets. PAK4 plays criti...
Autores principales: | Rane, Chetan, Senapedis, William, Baloglu, Erkan, Landesman, Yosef, Crochiere, Marsha, Das-Gupta, Soumyasri, Minden, Audrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309789/ https://www.ncbi.nlm.nih.gov/pubmed/28198380 http://dx.doi.org/10.1038/srep42555 |
Ejemplares similares
-
Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023) -
Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation
por: Mitchell, Shaneice, et al.
Publicado: (2021) -
XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017) -
A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015) -
Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha, et al.
Publicado: (2015)